Gen-AI Designed Enzymes for Pharma Manufacturing and Life Science Tools
Enzymes play a crucial role in driving market growth and profitability in the pharmaceutical industry. Developing industrial-grade enzymes that possess a balance of key properties becomes a top priority but remains challenging and time-consuming. Pando is here to solve that with AI and its internal screening platform.
- ProductIntroducing Saiyan-Phi29, a newly discovered high-fidelity polymerase
- ConferencePando will be attending ADLM
- ConferencePando will be presenting at the 6th mRNA-Based Therapeutics Summit in Boston.
- LinkedInWe’re excited to be featured on the Cypher AI Marketplace!
- LinkedInEnzyme development can be painfully slow.
- LinkedInTake a look at our new website!
- LinkedInWe just launched Pando Bioscience’s new website!
- SecurityPando is pursuing SOC 2 Type II certification
- ServicePando signed a new small-molecule biocatalysis deal
- ServicePando advances a DNA modifying enzyme program into phase II
- LinkedInStartup Boston spotlights Pando among Boston’s top biotech teams
- LinkedInPando on why the future of biotech is being built in Boston
Pando is an AI-driven synthetic biology company
Revolutionizing enzyme engineering for the pharmaceutical manufacturing and life science tools industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our AI models to efficiently optimize enzymes across multiple properties, delivering high-performing, industrial-grade enzymes that create and capture new market value.
The power of AI-guided iterative enzyme improvement
Every design–build–test–learn round feeds real wet-lab data back into our models, so results compound: each round finds more winning variants and pushes their performance higher than the last.
More winning variants every round
The number of validated hits jumps roughly 10× from the first to the second round — the model learns from each screen and proposes far better candidates next time.
Gains that random mutagenesis can’t match
Starting from random mutations (no AI), each AI-guided round stacks large, consistent activity improvements — well beyond what untargeted screening delivers.
Products and custom services
Supported by
